
What’s New with JAK Inhibitors?
In a exciting session at the EADV Congress 2024, leading experts unveiled the latest advancements and future prospects of Janus Kinase (JAK) inhibitors in treating
In a exciting session at the EADV Congress 2024, leading experts unveiled the latest advancements and future prospects of Janus Kinase (JAK) inhibitors in treating
This study was presented at the 33rd EADV Congress 2024 by Drs Sabine Zenker et al from the Dr Zenker Dermatology, Munich, Germany. In a
This study was presented at the 33rd EADV Congress 2024 by Drs Carolina Montero- Vilchez et al from the Virgen de las Nieves University Hospital,
This Case report was presented at the 33rd EADV Congress 2024 by Drs Letícia Scattone et al from the Complexo Hospitalar Heliópolis, São Paulo, Brazil.
This study was presented at the 33rd EADV Congress 2024 by Drs Serena Lambo et al from the University of Salerno, Department of Medicine, Surgery
This study was presented at the 33rd EADV Congress 2024 by Drs Kilian Eyerich et al from the University of Freiburg, Baden-Württemberg, Germany. An international
A slew of sessions were presented on Wednesday September 25th at the 33rd EADV Congress 2024 on new drugs and therapeutic options. Leading experts in
This study was presented by Dr Manu Shah et al from the Burnley General Teaching Hospital, Burnley, UK at the 104th Annual Meeting of the
This case report was presented by Dr Sid Orpin, Bhavnisha Patel, et al from the University Hospitals Birmingham NHS Trust, Birmingham, UK at the 104th
This study was presented by Drs Emily L Clarke, Derek Magee, Julia Newton-Bishop, William Merchant et al from the Translational and Clinical Research Institute, Newcastle